Digital Content

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. We’ll assume you’re ok with this, but you can opt out if you wish. See our 

Footer

Column Name Goes Here

Footer V2

2024 Event

Event Global

New HLTH Insights Programs

Become a Hosted Buyer

Become a Sponsor/Exhibitor

Apply for Media Pass

Promote Your Presence

2023 Event

Event Global Footer

Startup Opportunities

Hotel

2022 Event

LLC Global

2021 Event

LLC Menu Official

LLC Menu

There’s Still Untapped Potential of AI in Healthcare Innovation

No individual or specific organization can drive substantive change alone. It takes collaboration across the entire healthcare ecosystem. In this episode, Seema Kumar, the Chief Executive Officer of Cure, discusses the potential of artificial intelligence (AI) in healthcare. Seema shares her journey into healthcare innovation, emphasizing the crucial roles of science, technology, and storytelling in shaping the future of healthcare. She highlights the unique contribution of entrepreneurs as nimble actors driving change in the industry. The conversation delves into the collaborative nature of the healthcare ecosystem, where large organizations, entrepreneurs, academia, and government play complementary roles. Seema also emphasizes the need for sustained collaboration beyond crises and underlines the significance of AI in analyzing vast healthcare data for insights.  Tune in and explore the transformative possibilities at the intersection of AI and healthcare! About Seema Kumar:Seema Kumar is the Chief Executive Officer of Cure, a 300,000-square-foot facility aiming to advance healthcare through the development of cutting-edge solutions across medical devices, digital technologies, healthcare services, and bio-therapeutics. As the Global Head of Office of Innovation, Global Health, and Scientific Engagement, Seema leads global efforts to enhance public engagement with science and public health policy.  Prior to that role, Seema was responsible for Johnson &amp; Johnson&#39;s overall innovation reputation, positioning the R&amp;D pipeline, and leading COVID vaccine communications and external affairs efforts. Overall, she is a passionate advocate for science and women&#39;s empowerment, and serves on several boards and advisory committees. Things You’ll Learn:<ul><li>No individual or specific organization can drive substantive change alone; it takes collaboration across the entire healthcare ecosystem.</li><li>AI holds promise for healthcare, and leveraging its power requires large, representative, and complete datasets.</li><li>Entrepreneurs are restless with the status quo; they want to take risks and represent the leading edge of future healthcare.</li><li>The future of healthcare lies in sustained collaboration, AI-driven insights, and innovative solutions that address real-world challenges.</li><li>Storytelling, science, and technology combined can engage individuals in their own health and the health of the ecosystem.</li></ul>Resources:<ul><li>Connect with and follow Seema Kumar on <a href="https://www.linkedin.com/in/kumarseema/" target="_blank">LinkedIn</a>.</li><li>Follow Cure on <a href="https://www.linkedin.com/company/curenyc/" target="_blank">LinkedIn</a> and visit their <a href="https://cure.345pas.com/?" target="_blank">website</a>.</li><li>Learn more about Cure’s challenge <a href="https://wewillcure.com/xchange" target="_blank">here</a>!*</li></ul>*The submissions closed on October of 2023.

S4 E31: There’s Still Untapped Potential of AI in Healthcare Innovation

The Beat: Sanofi's Pattern Recognition in Vaccine Development

The vaccine business is highly competitive. But Sanofi stands out particularly well. In this episode, Deborah Glasser, Sanofi’s Head of Vaccines for North America, delves into Sanofi&#39;s extensive history in the vaccine business, focusing on areas such as influenza, neurology, and rare diseases. Deborah provides a glimpse into the groundbreaking RSV monoclonal antibody, Beyfortus, designed to protect infants from the leading cause of hospitalizations. She emphasizes the unique approach of using a monoclonal antibody for newborns, highlighting its potential to revolutionize RSV prevention. Deborah also touches on Sanofi&#39;s efforts in flu prevention, such as consumer education and the importance of immunization, especially for the vulnerable population aged 65 and older. She sheds light on Sanofi&#39;s innovative use of Artificial Intelligence (AI) in both drug discovery and commercial practices and shares Sanofi&#39;s interest in collaborating with startups, particularly those aligned with health system goals. Tune in and learn how Sanofi&#39;s dedication to science and technology shapes the landscape of vaccine development and public health. About Deborah Glasser:Deborah Glasser holds an MBA in Marketing and Finance from the University of Chicago Booth School of Business and a B.A. with honors from Tufts University. Deborah is currently the Head of Vaccines in North America at Sanofi. In this role, she spearheads a team committed to pursuing scientific breakthroughs, focusing on the development and enhancement of immunizations. Sanofi, a global pharmaceutical giant, places a strong emphasis on innovation, and Deborah plays a crucial role in driving the vision forward, expanding access to vaccines, and advancing public health initiatives throughout the U.S. and Canada. Drawing on a rich and varied professional background, Deborah brings more than a decade of experience to her current role. Her journey includes an illustrious 13-year tenure at Biogen, where she held diverse positions across its U.S., European, and global organizations. Notably, she played a key role in the successful launch of Tecfidera, an oral multiple sclerosis product that achieved remarkable success, generating $1.3 billion in U.S. sales within its first four full quarters on the market. Things You’ll Learn:<ul><li>The vaccine industry faces intense competition.</li><li>RSV stands as the primary reason for infant hospitalizations.</li><li>Approximately 70 out of every 100,000 individuals end up hospitalized due to the flu.</li><li>The flu poses a significant and serious risk, with an average of 36,000 deaths annually, potentially reaching 98,000 in severe seasons. These deaths are preventable.</li><li>It&#39;s crucial to recognize the seriousness of the flu and take preventive measures to avoid unnecessary fatalities.</li></ul> Resources:<ul><li>Connect with and follow Deborah Glasser on <a href="https://www.linkedin.com/in/deborah-glasser-b06643/" target="_blank">LinkedIn</a>.</li><li>Follow Sanofi on <a href="https://www.linkedin.com/company/sanofi/" target="_blank">LinkedIn</a> and visit their <a href="https://www.sanofi.com/en" target="_blank">website</a>.</li></ul>

S1 E6: The Beat: Sanofi's Pattern Recognition in Vaccine Development

Head of Vaccines, North America

Data for Better Patient Interactions—featuring Jordan Penn

Never again will providers have to start from zero again. In this episode, Jordan Penn, Senior Principal Sales Engineer at Inovalon, talks about how DataStream API can be a powerful digital integrated tool for care delivery and dives into the evolution of technologies of that sort in healthcare. DataStream API delivers patient-specific insights from existing EMRs to providers at the point of care to make the encounter more efficient and fruitful for both parties. Jordan provides a history lesson to explain how policies like the HITECH Act, the 21st Century Cures Act, and the FHIR standard have enabled better interoperability and access within the healthcare sector. On those connectivity grounds, DataStream API can serve clinically rich data in a better way to improve healthcare interactions. Tune in and learn about Inovalon’s digital solution that will make healthcare work easier for everybody! About Jordan Penn:In the past decade, Jordan Penn has spent his healthcare career as a storyteller, leveraging healthcare data and analytics to follow the patient journey, assist in research, and more. His expert knowledge of medical and pharmacy claims, lab data, and EMR/EHR data has made extraordinary contributions for his clients, and he has also been deeply involved with analyzing patient journeys to support HEOR studies. At Inovalon, Jordan is a Sr. Principal Sales Engineer, working cross-functionally between sales, product, engineering, marketing, and legal to bring new ideas to existing product offerings. When Jordan is not busy bringing healthcare data to life to inform and improve treatment, he enjoys quality time with his wife and daughter in New Jersey and is an avid weightlifter. Things You’ll Learn:<ul><li>DataStream can connect to existing EMRs and is EHR agnostic.</li><li>DataStream seeks to work with clients who lack or have too much data. </li><li>DataStream helps customers demystify or declutter what they have to assist providers with the insights they need when treating a patient.</li><li>The HITECH act incentivized providers and hospitals to adopt electronic health records, increasing from 10% of hospitals in 2008 to over 95% for hospitals and 85% of providers eight years later.</li><li>The 21st Century Cures Act vouched for interoperability and access to medical patient information without any particular need by the user.</li><li>DataStream can help doctors have information about their patients on their first visit and help them establish an excellent medical relationship with them.</li></ul> Resources:<ul><li>Connect with and follow Jordan Penn on <a href="https://www.linkedin.com/in/jordan-p-a7060896/" target="_blank">LinkedIn</a>.</li><li>Follow Inovalon on <a href="https://www.linkedin.com/company/inovalon/" target="_blank">LinkedIn</a>.</li><li>Visit the Inovalon <a href="https://www.inovalon.com/" target="_blank">Website</a>!</li></ul>

S3 Ep12: Data for Better Patient Interactions—featuring Jordan Penn

Senior Principal Sales Engineer

Striking the Right Balance: Regulating AI in Healthcare

Balancing regulation with innovation is crucial when it comes to AI and healthcare. In this episode, Shannon Klinger, the Chief Legal Officer and Corporate Secretary at Moderna, shares her inspiring journey, emphasizing the pivotal role of AI in Moderna&#39;s research and development. She highlights how AI and digital technology are at the core of Moderna&#39;s strategy, significantly increasing mRNA production for clinical trials, including during the COVID-19 pandemic. Shannon stresses that each day can impact and save patients&#39; lives, and she advocates for the harmony between speed and innovation. Finally, she explores the healthcare sector&#39;s need to find a balance between regulating AI and fostering innovation. Tune in to discover how Moderna leverages technology to democratize healthcare solutions, making a profound difference in people&#39;s lives. About Shannon Klinger:Shannon Thyme Klinger, the Chief Legal Officer and Corporate Secretary at Moderna is in charge of Moderna&#39;s legal and corporate compliance matters. Throughout her career, Shannon has been dedicated to improving long-term business performance, building trust with the public, ensuring access to medicine, and facilitating successful product launches. She is also a strong supporter of diversity, equity, and inclusion. Additionally, she served on the board of directors of the SIX Group in Switzerland from 2016 to 2020. Shannon earned her Juris Doctorate with honors from the University of North Carolina at Chapel Hill and a bachelor&#39;s degree in psychology from the University of Notre Dame. She is a member of the State Bar of Georgia and the District of Columbia Bar. Things You’ll Learn:<ul><li>Many individuals choose healthcare as their career path due to their personal experiences.</li><li>Regarding AI and healthcare, balancing regulation and innovation is crucial.</li><li>Organizations should ethically use AI applications for the benefit of the public.</li><li>Excessive regulation can hinder the pace of innovation, potentially leading to fewer lives being protected.</li><li>Imagine the impossible and make it possible.</li><li>Moderna&#39;s goal is to ensure that people worldwide, regardless of their place of birth, have access to high-quality treatments.</li></ul>Resources:<ul><li>Connect with and follow Shannon Klinger on <a href="https://www.linkedin.com/in/shannon-thyme-klinger/" target="_blank">LinkedIn</a>.</li><li>Follow Moderna on <a href="https://www.linkedin.com/company/modernatx/" target="_blank">LinkedIn</a>.</li><li>Discover the Moderna <a href="https://www.modernatx.com/?tc=soc_7y8qkt&amp;cc=1004" target="_blank">Website</a>.</li><li>Check out the mRNA Access <a href="https://mrna-access.modernatx.com/" target="_blank">Website</a>.</li><li>Visit Moderna’s Charitable Foundation <a href="https://www.modernatx.com/responsibility/moderna-foundation" target="_blank">Website</a>.</li><li>Listen to Shannon’s previous interview <a href="https://healthpodcastnetwork.com/episodes/outcomes-rocket/hlth-matters-using-mrna-technology-for-health-equity-with-shannon-thyme-klinger-chief-legal-officer-and-corporate-secretary-at-moderna/" target="_blank">here</a>.</li></ul>

S4 E11: Striking the Right Balance: Regulating AI in Healthcare

Chief Legal Officer

Podcast

S4 E31: There’s Still Untapped Potential of AI in Healthcare Innovation

FEATURING